Compass Pathways/CMPS

$11.71

9.64%
-
1D1W1MYTD1YMAX

About Compass Pathways

COMPASS Pathways plc is a United Kingdom-based mental healthcare company. The Company is developing psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression (TRD). The Company has developed COMP360, which is a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin. The Company's COMP360 has completed a Phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. This trial assessed the safety and efficacy of COMP360 psilocybin therapy in three doses: 1mg, 10mg, 25mg. The Company is also running a Phase II clinical trial of COMP360 psilocybin therapy for anorexia nervosa and post-traumatic stress disorder (PTSD). The Company is also developing its investigational COMP360 psilocybin therapy for the treatment of a range of mental health conditions, with an initial focus on TRD.

Ticker

CMPS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

George Goldsmith

Employees

114

Headquarters

Altrincham, United Kingdom

Compass Pathways Metrics

BasicAdvanced
$630.73M
Market cap
-
P/E ratio
-$2.59
EPS
2.53
Beta
-
Dividend rate

What the Analysts think about Compass Pathways

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 8 analysts.
241.59% upside
High $120.00
Low $16.00
$11.71
Current price
$40.00
Average price target

Compass Pathways Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-33.3M
17.67%
Profit margin
0%
-

Compass Pathways Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 54.28%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.73
-$0.57
-$0.62
-$0.67
-
Expected
-$0.59
-$0.68
-$0.69
-$0.43
-$0.33
Surprise
22.74%
-16.77%
-10.66%
54.28%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

Buy or sell Compass Pathways stock

Buy or sell Compass Pathways stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing